Financial Data and Key Metrics Changes - The company reported a decline in organic sales of 4.2% in Q2, which was below expectations, despite global consumption growing year over year [25][34] - Adjusted operating margin contracted by 10 basis points to 22.7%, with adjusted diluted EPS at $0.29 compared to $0.32 in the previous year [34][44] - Adjusted net income for Q2 was $560 million, reflecting an 8.3% decline year over year [44] Business Line Data and Key Metrics Changes - The Self Care business experienced a significant decline in organic sales of 5.9%, primarily due to lower volumes and unfavorable seasonal dynamics [36] - Skin Health and Beauty saw organic sales decrease by 3.7%, with consumption trends improving sequentially in the U.S. [38] - Essential Health reported a 2.4% decline in organic sales, with challenges in the mouthwash business despite gaining share online [41][42] Market Data and Key Metrics Changes - In the U.S., 83% of the company's business held or gained market share, particularly in the Self Care segment [25][37] - The allergy category faced challenges, with the U.S. experiencing the second-lowest allergy incidences on record [36] - Consumption of skin health and beauty brands stabilized globally for the first time in over a year, driven by growth in EMEA, Latin America, and Asia Pacific [26][39] Company Strategy and Development Direction - The company is undergoing a comprehensive review of strategic alternatives, focusing on optimizing its brand portfolio and improving operational performance [12][51] - There is a strong emphasis on simplifying operations and reducing complexity to enhance agility and decision-making [14][21] - The leadership team is prioritizing consumer-centric strategies and improving household penetration to drive market share [15][17] Management's Comments on Operating Environment and Future Outlook - Management acknowledged a tough quarter and revised guidance for 2025, expecting organic sales to decline in low single digits [27][45] - The company is committed to improving operational rigor and discipline, with a focus on enhancing efficiencies and driving margin improvements [30][31] - Management expressed confidence in the potential for turnaround, citing strong brand equity and a robust innovation pipeline [10][68] Other Important Information - The company has appointed new leaders to strengthen its leadership team, including a new Chief Technology and Data Officer [20] - The board is actively considering a range of strategic alternatives to unlock shareholder value [12][51] - The company is focused on executing its immediate priorities to drive improved performance and accelerate profitable growth [50] Q&A Session Summary Question: Discussion on complexity and focus on key brands - Management acknowledged the need to focus on the biggest brands and markets to drive growth, emphasizing the importance of execution excellence [56][57] Question: Surprises upon stepping into the role and areas of excitement - Management noted surprise at the self-induced complexity within the organization and expressed excitement about the potential for growth in focused areas like EMEA and LatAm [67][70] Question: Framework for unlocking value in challenging segments - Management confirmed that strategic alternatives and operational excellence efforts are aligned, focusing on consumer understanding and demand creation [76][78] Question: Measuring success in restructuring efforts - Success will be measured by consumer purchasing behavior and sequential improvement in market share, with a focus on leadership and capabilities [81][84]

Financial Data and Key Metrics Changes - The company reported a 4.2% decline in organic sales for Q2, which was below expectations, despite global consumption growing year over year [25][34] - Adjusted operating margin contracted by 10 basis points to 22.7%, with adjusted diluted EPS at $0.29 compared to $0.32 in the previous year [35][45] - Adjusted net income for Q2 was $560 million, reflecting an 8.3% decline year over year [45] Business Line Data and Key Metrics Changes - The Self Care business experienced a 5.9% decline in organic sales, primarily due to lower volumes and unfavorable seasonal dynamics [37] - Skin Health and Beauty saw a 3.7% decrease in organic sales, with consumption trends stabilizing globally for the first time in over a year [39][40] - Essential Health reported a 2.4% decline in organic sales, with challenges in the mouthwash business despite gaining share online [42][43] Market Data and Key Metrics Changes - In the U.S., 83% of the business held or gained market share, with notable performance in allergy products like Zyrtec [25][38] - Consumption trends improved sequentially in EMEA and Latin America, while North America and Asia Pacific faced challenges [40][72] - The allergy category in the U.S. recorded the second lowest incidences on record, impacting sales negatively [37] Company Strategy and Development Direction - The company is focusing on reducing complexity by streamlining its brand portfolio and prioritizing key markets and products [21][22] - A strategic review committee has been established to explore various alternatives for optimizing the brand portfolio [12] - The leadership aims to enhance operational efficiency and improve execution across major brands and markets [24][48] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the need for a consumer-centric approach and emphasized the importance of household penetration to drive market share [15][16] - The company revised its guidance for 2025, expecting organic sales to decline in low single digits due to current performance and market dynamics [46] - Management expressed confidence in the potential for turnaround, citing strong brand equity and a robust innovation pipeline [30][70] Other Important Information - The company has appointed new leaders to enhance capabilities in marketing, sales, digital, and AI [20][85] - A focus on flawless execution and faster decision-making is emphasized as critical to achieving growth [51][88] Q&A Session Summary Question: Discussion on complexity and focus on major brands - Management agreed on the need to focus on major brands and markets, acknowledging the complexity created within the organization [56][57] Question: Surprises upon stepping into the role and areas of excitement - Management noted surprise at the self-induced complexity and expressed excitement about the potential in EMEA and Latin America [68][72] Question: Framework for unlocking value and addressing low profitability segments - Management confirmed that strategic alternatives and operational excellence efforts are aligned, focusing on consumer understanding and demand creation [78][80] Question: Measuring success in restructuring efforts - Management stated that success will be measured by consumer purchasing behavior and sequential improvement in market share [84][88]

Financial Data and Key Metrics Changes - In 2024, the company achieved year-over-year organic sales growth of 1.5% with an adjusted operating income margin of 21.5% and adjusted diluted earnings per share of $1.14 [18] Business Segment Data and Key Metrics Changes - In the healthcare segment, the company expanded its leadership position and gained market share in nearly 80% of the segments, including key brands like Tylenol, Zyrtec, and Nicorette [16] - The essential health segment maintained a healthy mid-single-digit growth rate and delivered volume growth in North America, EMEA, and Latin America [16] - In skin health and beauty, the company grew both volume and value in EMEA and Latin America, despite not meeting expectations in North America and Asia Pacific [16] Market Data and Key Metrics Changes - The company reported significant improvements in consumer engagement and brand presence both in-store and online, contributing to overall growth [16] Company Strategy and Development Direction - The company established three strategic priorities for 2024: reaching more consumers, freeing up resources for competitive investment, and fostering a performance-driven culture [15] - The company aims to leverage superior science, expert recommendations, and consumer insights-led innovation to enhance brand growth in 2025 [18][19] - The company is focused on activating new revenue growth management capabilities to improve pricing and promotional strategies [19] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the dynamic external environment but expressed confidence in realizing compounding benefits from significant work done to date [21] - The company anticipates exciting opportunities ahead to create value for stakeholders and solidify its position as a consumer health leader [21] Other Important Information - The company is executing a two-year initiative to deliver $350 million of annualized cost savings by 2026 [17] - A new Chief Financial Officer, Amit Banati, has joined the company, expected to contribute to its next chapter [21] Q&A Session Summary Question: Why does the company not use GAAP earnings instead of adjusted non-GAAP earnings? - The company believes that presenting non-GAAP measures is relevant and useful for investors, as it allows for a better understanding of operating performance and easier comparison with peers in the industry [24]

Market Overview - The S&P 500 index is down approximately 9.5% from its high, while the Nasdaq Composite index has fallen 13.5% [1] - The stock market has experienced significant volatility, which may present investment opportunities in companies with strong long-term potential [2] Unity Software - Unity Software provides tools for developers to create video games and digital content, along with digital advertising tools [3] - Despite being a leader in the game-engine services space, Unity's stock has underperformed, down about 89% from its all-time high shortly after its IPO in 2020 [4][5] - In Q4, Unity's sales declined 25% year over year to approximately $457 million, with a net loss of $127 million [6] - However, revenue from Unity's core strategic portfolio increased 4% year over year to $442 million, indicating potential for recovery [7] - The company is undergoing restructuring and strategic shifts, including changes to its digital advertising network and the rollout of a new AI platform [7] - Unity's shares are considered a worthwhile buy ahead of its first-quarter earnings release on May 7 [8] Kenvue - Kenvue, a spinoff from Johnson & Johnson, has not performed as expected, down more than 15% from its all-time high [9] - The company reported 1.9% organic sales growth in its self-care segment and 4.1% growth in essential health, but a decline of 1.9% in the skin health and beauty segment [11] - Kenvue increased its marketing budget to 10.6% of sales in 2024, but recovery is slower than anticipated [12] - There are signs of improvement in the skin health and beauty segment, with organic sales rising 2.6% in Q4 2024 [13] - Kenvue trades at just below 21 times estimated free cash flow for 2025, close to fair value for a mature consumer staple [14] - The stock offers a 3.6% dividend yield, making it attractive for value investors despite low growth prospects [14]